Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
thalidomide + cyclophosphamide + prednisone
- Development stage
- Phase 2
- Lead developer
- Grünenthal
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
An all-oral combination regimen consisting of thalidomide, cyclophosphamide, and prednisone. This combination therapy is used primarily for treating hematological disorders including idiopathic multicentric Castleman disease (iMCD), peripheral T-cell lymphoma (PTCL), and multiple myeloma. The regimen works through multiple mechanisms: thalidomide inhibits angiogenesis and modulates inflammatory cytokines, cyclophosphamide destroys rapidly dividing cells, and prednisone enhances chemotherapy effectiveness.
- Other names
- TCP
02
Targets
CRBN (Cereblon)DNAGR (Glucocorticoid receptor)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on thalidomide + cyclophosphamide + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on thalidomide + cyclophosphamide + prednisone.